S&P Futures
3,900.50 -3.25 (-0.08%) Dow Futures
31,414.00 -7.00 (-0.02%) Nasdaq Futures
12,025.25 -15.25 (-0.13%) Russell 2000 Futures
1,770.30 +0.50 (+0.03%) Crude Oil
110.96 +1.39 (+1.27%) Gold
1,827.90 +3.10 (+0.17%)
Organovo Holdings, Inc. (ONVO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7700 |
| Open | 1.7900 |
| Bid | 1.8300 x 1200 |
| Ask | 1.9700 x 1300 |
| Day's Range | 1.7700 - 1.8650 |
| 52 Week Range | 1.7300 - 9.6200 |
| Volume | |
| Avg. Volume | 24,709 |
| Market Cap | 15.931M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3970 |
| Earnings Date | Feb 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Organovo Achieves 3D Tissue Model for Crohn’s Disease
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo
- Motley Fool
Why Organovo Holdings, Inc. Stock Soared 49.7% This Week
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
- GlobeNewswire
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting
